Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

New Na+/H+-exchange inhibitors from Fujisawa

Sep. 26, 1997

FDA grants final marketing approval for Corlopam

Sep. 25, 1997

Irbesartan introduced in first markets

Sep. 25, 1997

VasoCare reduces stress in animal model of hypertension

Sep. 24, 1997

Novel iron complex available for licensing from MoliChem Medicines

Sep. 24, 1997

Merck KGaA claims new Na+/H+-exchange inhibitors

Sep. 24, 1997

Cardizem Monovial approved for U.S. marketing

Sep. 23, 1997

Andrx's extended-release diltiazem receives tentative approval

Sep. 22, 1997

Dual IL-6/NO production inhibitors prepared at Takeda

Sep. 19, 1997

Dual ACE/NEP inhibitors described by Zambon

Sep. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...